The primary objective of this study is to assess the safety and tolerability of KRN23 after a single intravenous (IV) and subcutaneous (SC) administration in XLH patients.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Enrollment
42
Yale University School of Medicine
New Haven, Connecticut, United States
General Clinical Research Center, Indiana University School of Medicine
Indianapolis, Indiana, United States
Duke Clinical Research Unit
Durham, North Carolina, United States
University of Texas Health Science Center at Houston
Houston, Texas, United States
Safety and tolerability
AEs, etc
Time frame: Up to 7 weeks after dosing (maximally 11 weeks)
Effect to pharmacodynamic parameter
Change in Serum Phosphate
Time frame: Up to 7 weeks after dosing (maximally 11 weeks)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.